# Infliximab (Remicade) for Patients With Acute Kawasaki Disease

> **NCT00271570** · PHASE1 · COMPLETED · sponsor: **University of California, San Diego** · enrollment: 24 (actual)

## Conditions studied

- Kawasaki Disease

## Interventions

- **DRUG:** Infliximab (Remicade)
- **BIOLOGICAL:** Intravenous immunoglobulin (IVIG)

## Key facts

- **NCT ID:** NCT00271570
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2010-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00271570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00271570, "Infliximab (Remicade) for Patients With Acute Kawasaki Disease". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT00271570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*